CorMedix IncNASDAQ:CRMD
- LAST PRICE4.3900
- TODAY'S CHANGE (%)-0.0400 (-0.9029%)
- Bid / Lots4.3100/ 11
- Ask / Lots4.3900/ 3
- Open / Previous Close4.4300 / 4.4300
- Day Range
- 52 Week Range
- Volume519,171
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 76128 | 4.43 |
| 09:39 ET | 1308 | 4.425 |
| 09:41 ET | 100 | 4.42 |
| 09:45 ET | 2878 | 4.46 |
| 09:52 ET | 800 | 4.4699 |
| 09:56 ET | 300 | 4.43 |
| 09:59 ET | 2585 | 4.43 |
| 10:03 ET | 1330 | 4.44 |
| 10:08 ET | 200 | 4.435 |
| 10:10 ET | 200 | 4.436 |
| 10:15 ET | 600 | 4.425 |
| 10:19 ET | 200 | 4.4297 |
| 10:24 ET | 1200 | 4.425 |
| 10:26 ET | 100 | 4.425 |
| 10:28 ET | 203 | 4.4214 |
| 10:32 ET | 1001 | 4.415 |
| 10:33 ET | 450 | 4.41 |
| 10:42 ET | 500 | 4.405 |
| 10:44 ET | 100 | 4.405 |
| 10:46 ET | 572 | 4.415 |
| 10:50 ET | 1100 | 4.425 |
| 10:53 ET | 100 | 4.42 |
| 10:57 ET | 300 | 4.41 |
| 11:02 ET | 4751 | 4.385 |
| 11:09 ET | 2800 | 4.38 |
| 11:11 ET | 1950 | 4.3608 |
| 11:15 ET | 100 | 4.35 |
| 11:18 ET | 1173 | 4.36 |
| 11:22 ET | 900 | 4.38 |
| 11:24 ET | 1000 | 4.3891 |
| 11:27 ET | 2108 | 4.38 |
| 11:33 ET | 100 | 4.38 |
| 11:36 ET | 100 | 4.38 |
| 11:40 ET | 100 | 4.385 |
| 11:42 ET | 899 | 4.3801 |
| 11:45 ET | 700 | 4.37 |
| 11:47 ET | 29043 | 4.3712 |
| 11:49 ET | 100 | 4.38 |
| 11:51 ET | 100 | 4.38 |
| 11:56 ET | 100 | 4.385 |
| 11:58 ET | 17058 | 4.38 |
| 12:00 ET | 100 | 4.385 |
| 12:02 ET | 1917 | 4.38 |
| 12:03 ET | 100 | 4.375 |
| 12:07 ET | 244 | 4.375 |
| 12:09 ET | 16452 | 4.38 |
| 12:12 ET | 1017 | 4.37 |
| 12:14 ET | 4253 | 4.375 |
| 12:20 ET | 300 | 4.37 |
| 12:21 ET | 100 | 4.37 |
| 12:23 ET | 4764 | 4.365 |
| 12:25 ET | 200 | 4.37 |
| 12:39 ET | 114 | 4.37 |
| 12:45 ET | 2995 | 4.368 |
| 12:48 ET | 200 | 4.365 |
| 12:50 ET | 100 | 4.36 |
| 12:52 ET | 400 | 4.365 |
| 12:54 ET | 544 | 4.375 |
| 12:56 ET | 300 | 4.37 |
| 12:59 ET | 100 | 4.375 |
| 01:01 ET | 2595 | 4.375 |
| 01:08 ET | 100 | 4.375 |
| 01:10 ET | 100 | 4.375 |
| 01:12 ET | 1100 | 4.375 |
| 01:15 ET | 200 | 4.38 |
| 01:19 ET | 100 | 4.375 |
| 01:24 ET | 1295 | 4.37 |
| 01:26 ET | 800 | 4.37 |
| 01:28 ET | 1092 | 4.38 |
| 01:30 ET | 1495 | 4.365 |
| 01:32 ET | 26945 | 4.398 |
| 01:33 ET | 300 | 4.385 |
| 01:35 ET | 700 | 4.385 |
| 01:39 ET | 300 | 4.39 |
| 01:44 ET | 100 | 4.395 |
| 01:46 ET | 200 | 4.3901 |
| 01:48 ET | 1100 | 4.39 |
| 01:50 ET | 100 | 4.39 |
| 01:53 ET | 100 | 4.39 |
| 01:57 ET | 2110 | 4.3901 |
| 02:00 ET | 1322 | 4.38 |
| 02:02 ET | 965 | 4.375 |
| 02:04 ET | 100 | 4.37 |
| 02:06 ET | 300 | 4.38 |
| 02:08 ET | 200 | 4.375 |
| 02:09 ET | 200 | 4.37 |
| 02:11 ET | 302 | 4.375 |
| 02:15 ET | 935 | 4.375 |
| 02:18 ET | 200 | 4.39 |
| 02:20 ET | 1100 | 4.3952 |
| 02:24 ET | 636 | 4.395 |
| 02:29 ET | 1095 | 4.395 |
| 02:31 ET | 18410 | 4.43 |
| 02:33 ET | 419 | 4.42 |
| 02:36 ET | 5627 | 4.415 |
| 02:40 ET | 8003 | 4.39 |
| 02:42 ET | 100 | 4.39 |
| 02:44 ET | 200 | 4.4 |
| 02:45 ET | 200 | 4.395 |
| 02:47 ET | 2000 | 4.385 |
| 02:51 ET | 100 | 4.38 |
| 02:54 ET | 150 | 4.384 |
| 02:56 ET | 100 | 4.38 |
| 02:58 ET | 100 | 4.385 |
| 03:00 ET | 104 | 4.38 |
| 03:03 ET | 100 | 4.38 |
| 03:05 ET | 2616 | 4.39 |
| 03:14 ET | 5919 | 4.37 |
| 03:16 ET | 545 | 4.375 |
| 03:18 ET | 100 | 4.375 |
| 03:20 ET | 1103 | 4.385 |
| 03:23 ET | 115 | 4.385 |
| 03:25 ET | 969 | 4.38 |
| 03:27 ET | 358 | 4.38 |
| 03:30 ET | 180 | 4.3899 |
| 03:32 ET | 100 | 4.38 |
| 03:36 ET | 4421 | 4.385 |
| 03:39 ET | 3430 | 4.375 |
| 03:41 ET | 200 | 4.375 |
| 03:43 ET | 2162 | 4.37 |
| 03:45 ET | 225 | 4.3701 |
| 03:48 ET | 700 | 4.375 |
| 03:50 ET | 656 | 4.37 |
| 03:52 ET | 4910 | 4.385 |
| 03:54 ET | 4442 | 4.395 |
| 03:56 ET | 2137 | 4.395 |
| 03:57 ET | 6908 | 4.405 |
| 03:59 ET | 117849 | 4.39 |
Jun 19, 2024
DJ CorMedix Price Target Maintained With a $10.00/Share by Needham, from 5:55AM ET on Wednesday Jun 19, 2024 by Dow Jones
5:55AM ET on Wednesday Jun 19, 2024 by Dow Jones
Jun 18, 2024
CorMedix Inc. Receives FDA Feedback on Potential Label Expansion, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 6, 2024
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath, from 8:30AM ET on Thursday Jun 06, 2024 by Dow Jones
8:30AM ET on Thursday Jun 06, 2024 by Dow Jones
May 28, 2024
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider, from 8:30AM ET on Tuesday May 28, 2024 by Dow Jones
8:30AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 241.4M | -4.7x | --- |
Cipla Ltd | 14.9B | 0.0x | --- |
Assembly Biosciences Inc | 95.7M | -1.4x | --- |
Calliditas Therapeutics AB | 1.2B | -20.8x | --- |
Zevra Therapeutics Inc | 182.5M | -3.2x | --- |
Incannex Healthcare Inc | 55.6M | 0.0x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Head of Clinical and Medical Affairs
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Commercial Officer
- Erin Mistry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $241.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.60 |
EPS | $-0.93 |
Book Value | $1.28 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
